Prior treatment with anti-PD- or anti-PD-L therapeutic antibody, or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met:\r\n** Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA- (NCI Common Terminology Criteria for Adverse Events [CTCAE] grade  and )
Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA- may be enrolled provided the following requirements are met:\r\n* Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose to randomization\r\n* No history of severe immune-related adverse effects (CTCAE Grade  and ) from anti-CTLA-
Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met: minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose, and no history of severe immune-related adverse effects from anti-CTLA- (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade  and )
Patients who have received prior treatment with anti-CTLA- antibody may be enrolled, provided the following requirements are met:\r\n* >  weeks from the last dose\r\n* No history of severe immune-related adverse effects from anti-CTLA- antibody (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade  and )
Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met:\r\n** Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA- (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade  and )
Prior treatment with anti?cytotoxic T-lymphocyte-associated protein  (CTLA-) therapeutic agents (e.g. ipilimumab)
Patients that have undergone treatment with anti-CTLA- (Cytotoxic T-Lymphocyte Antigen ) antibody must have at least  months from last dose of CTLA- antibody before they can be enrolled into this study
Received treatment with anti-CTLA- antibody within  days prior to the start of CMP-.
Prior therapy with anti-PD-, or anti-PD-L therapeutic antibody or pathway targeting agents.\r\n* Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met:\r\n** Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose.\r\n** No history of severe immune-related adverse effects from anti-CTLA- (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade  and ).
Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway targeting agents; but patients who have received prior treatment with antiCTLA- may be enrolled, provided the following requirements are met: () minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose; () no history of severe immune-related adverse effects from anti-CTLA  (National Cancer Institute [NCI] Common Terminology for Cancer Adverse Effects CTCAE] grade  and )
(Atezolizumab-related exclusion) Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway targeting agents a) Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met: Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose. No history of severe immune-related adverse effects from anti-CTLA  (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade  and )
Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway targeting agents\r\n* Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met:\r\n** Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA  (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade  and )
PHASE I: Patients who have previously received anti-cytotoxic T-lymphocyte antigen (CTLA)- antibody therapy
Patients who have received prior treatment with anti-PD-, or anti-PD-L therapeutic antibody, or pathway -targeting agents\r\n* Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met:\r\n** Minimum of  weeks from the first dose of anti-CTLA- and > weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA- (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade  and )
Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway targeting agents. Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met: Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose. No history of severe immune-related adverse effects from anti-CTLA  (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade  and ).
Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway-targeting agents\r\n* Note:\r\n** Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met:\r\n*** Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose\r\n*** No history of severe immune-related adverse effects from anti-CTLA- (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade  and )
Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met:\r\n** Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA- (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] grade  and )
Has received prior therapy with an anti-CTLA agent
Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met:\r\n** Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA- (NCI CTCAE grade  and )
Patients with known immune impairment who may be unable to respond to anti-cytotoxic T-lymphocyte antigen  (CTLA ) antibody
Patients who have received prior treatment with anti?CTLA- may be enrolled, provided the following requirements are met:\r\n* Minimum of  weeks from the first dose of anti?CTLA- and >  weeks from the last dose\r\n* No history of severe immune-related adverse effects from anti?CTLA- (CTCAE grade  and )
Study participants with known immune impairment who may be unable to respond to anti-cytotoxic T-lymphocyte antigen  (CTLA ) antibody and/or anti-PD- antibody
Patients with known immunodeficiency disorder, or presumed to be unable to respond to anti-cytotoxic T-lymphocyte-associated protein  (CTLA ) monoclonal antibody (mAb)
Patients with known immune impairment who may be unable to respond to anti-cytotoxic T-lymphocyte-associated protein  (CTLA ) antibody
History of prior treatment with anti-cytotoxic T-lymphocyte-associated protein  (CTLA) blocking antibody
Prior treatment with anti-CTLA- therapeutic antibody or pathway-targeting agents
Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-cytotoxic T lymphocyte-associated antigen (CTLA-) may be enrolled, provided the following requirements are met:\r\n** Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last\r\ndose\r\n** No history of severe immune-related adverse effects from anti-CTLA- (National Cancer Institute [NCI] common terminology criteria for adverse events [CTCAE] grade  and )
Previous treatment with anti-cytotoxic T-lymphocyte-associated protein  (CTLA-) antibody or cancer vaccine
Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein (CTLA)- antibody if treatment failure was due to adverse events (AEs); if a subject was discontinued from the prior anti-CTLA- treatment due to an AE or serious adverse event (SAE), regardless of the type of event, that discontinuation constitutes an exclusion criterion; if AEs were serious enough to require a subjects withdrawal from prior treatment, the subject should be excluded from this study
Prior treatment with anti-PD-, or anti-PD-L therapeutic antibody or pathway-targeting agents or eribulin\r\n* Patients who have received prior treatment with anti-CTLA- may be enrolled, provided the following requirements are met:\r\n** Minimum of  weeks from the first dose of anti-CTLA- and >  weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA- (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version .)
Prior anti-PD-L therapies are excluded\r\n* Patients who have received prior treatment with immunotherapy including anti-PD- anti-CTLA- may be enrolled, provided that there was no history of severe immune-related adverse effects (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] grade  and )
No history of severe immune-related adverse effects from anti CTLA  (CTCAE Grade  and )
Treatment with any immunomodulatory medication within  weeks of initiation of study therapy, except for anti-tumor therapy (e.g., anti-cytotoxic T-lymphocyte-associated antigen  [CTLA-])
Patients with known immune impairment who may be unable to respond to anti-CTLA- antibody
Patients with known immune impairment who may be unable to respond to anti-cytotoxic T-lymphocyte antigen  (CTLA ) antibody
Any subject with the following reported drug-related adverse events on anti- Cytotoxic T-Lymphocyte Antigen  (anti-CTLA) will not be permitted on study: hepatic, diarrhea/colitis or endocrine adverse events (AE)s Grade ? , any other non-laboratory immune-related AE ? Grade . Subjects must have minimum  week washout period between the last dose of anti-CTLA and the first dose Urelumab (BMS-)
Prior treatment with an anti-CTLA- agent
